{"id":352,"date":"2019-12-28T22:27:33","date_gmt":"2019-12-29T04:27:33","guid":{"rendered":"https:\/\/www.improvingyourodds.com\/wp\/?p=352"},"modified":"2020-01-10T21:15:56","modified_gmt":"2020-01-11T03:15:56","slug":"pd-1-versus-pd-l1-inhibitors-which-have-better-outcomes","status":"publish","type":"post","link":"https:\/\/www.improvingyourodds.com\/wp\/pd-1-versus-pd-l1-inhibitors-which-have-better-outcomes\/","title":{"rendered":"PD-1 versus PD-L1 Inhibitors, which immunotherapy type drug has better outcomes?"},"content":{"rendered":"<p>Immunotherapy drugs are becoming increasingly popular choices for treating certain cancers. A recent study compares both the overall survival (OS) and progression-free survival (PFS) of both PD-1 and PD-L1 inhibitors.<\/p>\n<p><!--more--><\/p>\n<p>The following article analyzed data from 19 different studies with over 11,000 patients receiving either PD-1 inhibitors such as nivolumab (Opdivo) and pembrolizumab (Keytruda), or PD-L1 inhibitors such as avelumab (Bavencio) or atezolizumab (Tecentriq). What they found was clear differences in both OS and PFS with PD-1 inhibitors being clearly superior. Both immunotherapy drugs (PD-1 and PD-L1) had similar side effects.<\/p>\n<p>If\u00a0 you have read <a href=\"https:\/\/amzn.to\/368Jt3F\" target=\"_blank\" rel=\"noopener noreferrer\"><em>Cancer: Improving Your Odds<\/em><\/a> you know there are natural ways to <em>improve your odds<\/em> (response) to these checkpoint inhibitor type drugs. See Chapter 2 of the book for more information. You can also find out more about the book on the <a href=\"https:\/\/www.improvingyourodds.com\/wp\/book-information-cancerimproving-your-odds\/\">information page<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<div class=\"su-box su-box-style-default\" id=\"\" style=\"border-color:#000000;border-radius:3px;\"><div class=\"su-box-title\" style=\"background-color:#333333;color:#FFFFFF;border-top-left-radius:1px;border-top-right-radius:1px\">Citations<\/div><div class=\"su-box-content su-u-clearfix su-u-trim\" style=\"border-bottom-left-radius:1px;border-bottom-right-radius:1px\">\n<p>MedPage Today &#8220;<a href=\"https:\/\/www.medpagetoday.com\/hematologyoncology\/othercancers\/84113\" target=\"_blank\" rel=\"noopener noreferrer\">PD-1 vs PD-L1 Inhibitors: Do Outcomes Differ?<\/a>&#8220;<\/p>\n<p>Duan J, Cui L, Zhao X, et al. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. Published online December 26, 2019. <a href=\"https:\/\/doi.org\/10.1001\/jamaoncol.2019.5367\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org\/10.1001\/jamaoncol.2019.5367<\/a><\/p>\n<\/div><\/div>\n<p>&nbsp;<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content --><!-- AddThis Related Posts generic via filter on the_content -->","protected":false},"excerpt":{"rendered":"<p>Immunotherapy drugs are becoming increasingly popular choices for treating certain cancers. A recent study compares both the overall survival (OS) and progression-free survival (PFS) of both PD-1 and PD-L1 inhibitors.<!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --><!-- AddThis Related Posts generic via filter on get_the_excerpt --><\/p>\n","protected":false},"author":1,"featured_media":353,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-352","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"jetpack_featured_media_url":"https:\/\/www.improvingyourodds.com\/wp\/wp-content\/uploads\/2019\/12\/Immunotherapy-ISS_12903_15768.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.improvingyourodds.com\/wp\/wp-json\/wp\/v2\/posts\/352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.improvingyourodds.com\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.improvingyourodds.com\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.improvingyourodds.com\/wp\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.improvingyourodds.com\/wp\/wp-json\/wp\/v2\/comments?post=352"}],"version-history":[{"count":5,"href":"https:\/\/www.improvingyourodds.com\/wp\/wp-json\/wp\/v2\/posts\/352\/revisions"}],"predecessor-version":[{"id":403,"href":"https:\/\/www.improvingyourodds.com\/wp\/wp-json\/wp\/v2\/posts\/352\/revisions\/403"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.improvingyourodds.com\/wp\/wp-json\/wp\/v2\/media\/353"}],"wp:attachment":[{"href":"https:\/\/www.improvingyourodds.com\/wp\/wp-json\/wp\/v2\/media?parent=352"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.improvingyourodds.com\/wp\/wp-json\/wp\/v2\/categories?post=352"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.improvingyourodds.com\/wp\/wp-json\/wp\/v2\/tags?post=352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}